Wednesday, August 10, 2022
Home Tags PP Defence Therapeutics

PP Defence Therapeutics Related News

Defence Therapeutics receives US patent for its ADC Platform Technology

Defence Therapeutics receives US patent for its ADC Platform Technology

In an exciting development, Defence Therapeutics has received a US patent covering its ADC Platform Technology. In the latest announcement on August 8th, 2022, Defence...
cancer cells

ACCUTOXTM effectively eliminates cancer cells by eliciting DNA damage

In a potentially monumental breakthrough in the war against cancer, Defence Therapeutics has revealed that its leading AccuTOXTM compound effectively kills cancer cells through...
cervical cancer vaccine

ACCUVAC-PTE7 cervical cancer vaccine provides complete protection

In a groundbreaking advancement in the treatment of cancer, Defence Therapeutics has revealed that the company’s AccuVAC-PTE7 cervical cancer vaccine completely protects against the...
cancer

Defence Therapeutics provides an update on its numerous anti-cancer projects

Biotechnology pioneers Defence Therapeutics outline its current research and development progress in a plethora of anti-cancer endeavours. In Q1 of 2022, Defence signed an agreement...
Defence Therapeutics: Accelerating the fight against cancer and infectious diseases

Defence Therapeutics: Accelerating the fight against cancer and infectious diseases

Defence Therapeutics outlines how it is actively looking to continue the development of its product pipeline in partnership with large pharmaceutical companies. Defence Therapeutics, a...
AccuTOXTM

Defence Therapeutics move closer to AccuTOXTM Phase I clinical trial

Defence Therapeutics has established an agreement with CATO SMS, who will advise on submitting the company’s clinical application to Health Canada to initiate a...
HPV vaccine

Defence Therapeutics’ HPV vaccine achieves a higher humoral response than Gardasil-9

Canadian biotechnology company Defence Therapeutics has revealed that its novel HPV vaccine has demonstrated a higher humoral response than the Gardasil-9 vaccine. The company’s new...
Defence Therapeutics achieves major milestone with anti-cancer molecule 

Defence Therapeutics achieves major milestone with anti-cancer molecule 

Biotechnology company Defence Therapeutics has announced the start of its final step in GLP studies on its anti-cancer AccuTOXTM molecule at Eurofins Advinus Limited...
CRISPR

AccumTM platform greatly enhances CRISPR gene-editing technology

Defence Therapeutics has announced that its AccumTM platform can potently enhance Cas9 delivery in target cells, significantly advancing CRISPR gene-editing technology. The CRISPR technology offers...
Defence Therapeutics: changing the face of vaccines using AccumTM technology

Defence Therapeutics: changing the face of vaccines using AccumTM technology

Biotechnology specialists Defence Therapeutics are changing the face of vaccines using its AccumTM technology to enable precise delivery of proteins of pharmacological interest to...

Defence Therapeutics: Optimising drug efficacy with AccumTM technology

Health Europa is excited to introduce the latest captivating eBook from industry pioneers of the biotechnology sector, Defence Therapeutics, who comprehensively elucidate their revolutionary...
Defence Therapeutics

Defence Therapeutics announces exciting addition to its board of directors

Biotechnology specialists Defence Therapeutics has revealed today that Dr Riam Shammaa has been appointed to its board of directors. Dr Riam Shammaa, MD, is a...
new COVID vaccine

Defence Therapeutics successfully test new COVID vaccine

Defence Therapeutics has sensationally revealed that they have successfully completed studies of their new COVID vaccine in a non-rodent rabbit model. The innovative new COVID...
breast cancer

AccumTM variants successfully increase breast cancer treatment potency

Biotechnology experts Defence Therapeutics have revealed strong in vitro results of its AccumTM variants on the ADC breast cancer treatment called Enhertu® (fam-trastuzumab-deruxtecan-nxki), which...
cancer vaccine

Defence Therapeutics prepares to test its DC cancer vaccine against melanoma

Defence Therapeutics is finalising all required steps in preparation for a pre-IND meeting to initiate a phase I trial against melanoma using its DC cancer...
breast cancer treatment

Defence Therapeutics embark on next stage of breast cancer treatment development

In a groundbreaking development, pioneering biotechnology company Defence Therapeutics has announced today it will be performing the final necessary studies before entering a Phase...
new COVID vaccine

Defence Therapeutics’ new COVID vaccine achieves successful testing

Biotechnology experts Defence Therapeutics have sensationally announced that their new COVID vaccine has demonstrated effectiveness in a non-rodent model. The new COVID vaccine – called...
HPV vaccine

Defence Therapeutics unveil novel HPV vaccine development programme

Industry-leading biotechnology company Defence Therapeutics has revealed that it will be establishing a high priority programme to develop a new HPV vaccine for cervical...
Defence Therapeutics receives US patent for its ADC Platform Technology

Versatile Accum technology for various immune-oncology needs

Defence Therapeutics explains how its Accum™ technology can enhance the delivery of tumour and infectious disease-specific therapeutics. The principal technology developed by Defence Therapeutics (DT)...
drug-delivery-Defence-Therapeutics

Defence Therapeutics selects new variants to optimise drug delivery

Following a thorough evaluation process, Defence Therapeutics has selected the eight most successful variants of its Accum™ drug delivery technology. Biotechnology company Defence Therapeutics continually works...

Health Special Reports

Health eBooks

Health Partners

Pin It on Pinterest